|
1
|
Cook BJ and Bartley GB: Treatment options and future prospects for the management of eyelid malignancies: An evidence-based update. Ophthalmology. 108:2088–2098, 2099-2100. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wang L, Shan Y, Dai X, You N, Shao J, Pan X, Gao T and Ye J: Clinicopathological analysis of 5146 eyelid tumours and tumour-like lesions in an eye centre in South China, 2000–2018: A retrospective cohort study. BMJ Open. 11:e0418542021. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kaliki S, Ayyar A, Dave TV, Ali MJ, Mishra DK and Naik MN: Sebaceous gland carcinoma of the eyelid: Clinicopathological features and outcome in Asian Indians. Eye (Lond). 29:958–963. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Watanabe A, Sun MT, Pirbhai A, Ueda K, Katori N and Selva D: Sebaceous carcinoma in Japanese patients: Clinical presentation, staging and outcomes. Br J Ophthalmol. 97:1459–1463. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Cicinelli MV and Kaliki S: Ocular sebaceous gland carcinoma: An update of the literature. Int Ophthalmol. 39:1187–1197. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Esmaeli B, Nasser QJ, Cruz H, Fellman M, Warneke CL and Ivan D: American Joint Committee on Cancer T category for eyelid sebaceous carcinoma correlates with nodal metastasis and survival. Ophthalmology. 119:1078–1082. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhou C, Shi Y, Chai P, Wu F, Xia W, He X, Shi Y, Huang H, Jia R and Fan X: Contemporary update of overall prognosis and nomogram to predict individualized survival for Chinese patients with eyelid sebaceous carcinoma. EBioMedicine. 36:221–228. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Shields JA, Demirci H, Marr BP, Eagle RC Jr and Shields CL: Sebaceous carcinoma of the eyelids: Personal experience with 60 cases. Ophthalmology. 111:2151–2157. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hirano T, Yunoki T, Furusawa Y, Tabuchi Y and Hayashi A: Bioinformatics analysis of the microRNA-mRNA network in sebaceous gland carcinoma of the eyelid. Mol Med Rep. 23:232021.PubMed/NCBI
|
|
10
|
Bhardwaj M, Sen S, Chosdol K, Sharma A, Pushker N, Kashyap S, Bakhshi S and Bajaj MS: miRNA-200c and miRNA-141 as potential prognostic biomarkers and regulators of epithelial-mesenchymal transition in eyelid sebaceous gland carcinoma. Br J Ophthalmol. 101:536–542. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Dang X, Lin H, Li Y, Guo X, Yuan Y, Zhang R, Li X, Chai D and Zuo Y: MicroRNA profiling in BEAS-2B cells exposed to alpha radiation reveals potential biomarkers for malignant cellular transformation. Toxicol Res (Camb). 9:834–844. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kocyigit I, Taheri S, Sener EF, Eroglu E, Ozturk F, Unal A, Korkmaz K, Zararsiz G, Sipahioglu MH, Ozkul Y, et al: Serum micro-rna profiles in patients with autosomal dominant polycystic kidney disease according to hypertension and renal function. BMC Nephrol. 18:1792017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Adams JC and Lawler J: The thrombospondins. Cold Spring Harb Perspect Biol. 3:a0097122011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Huang C, Zhou X, Li Z, Liu H, He Y, Ye G and Huang K: Downregulation of thrombospondin-1 by DNA hypermethylation is associated with tumor progression in laryngeal squamous cell carcinoma. Mol Med Rep. 14:2489–2496. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Huang WT, Chong IW, Chen HL, Li CY, Hsieh CC, Kuo HF, Chang CY, Chen YH, Liu YP, Lu CY, et al: Pigment epithelium-derived factor inhibits lung cancer migration and invasion by upregulating exosomal thrombospondin 1. Cancer Lett. 442:287–298. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lin T, Zhu L, Zhou B, Xie L, Lv J, Dong L and He Y: Establishment and characterization of a cell line from human adenoid cystic carcinoma of the lacrimal glands and a nude mouse transplantable model. Oncol Rep. 33:2797–2806. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Agarwal V, Bell GW, Nam JW and Bartel DP: Predicting effective microRNA target sites in mammalian mRNAs. eLife. 4:42015. View Article : Google Scholar
|
|
19
|
Liu W and Wang X: Prediction of functional microRNA targets by integrative modeling of microRNA binding and target expression data. Genome Biol. 20:182019. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Pe'er J: Pathology of eyelid tumors. Indian J Ophthalmol. 64:177–190. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Satomura H, Ogata D, Arai E and Tsuchida T: Dermoscopic features of ocular and extraocular sebaceous carcinomas. J Dermatol. 44:1313–1316. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Muqit MM, Foot B, Walters SJ, Mudhar HS, Roberts F and Rennie IG: Observational prospective cohort study of patients with newly-diagnosed ocular sebaceous carcinoma. Br J Ophthalmol. 97:47–51. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Buitrago W and Joseph AK: Sebaceous carcinoma: The great masquerader: Emgerging concepts in diagnosis and treatment. Dermatol Ther. 21:459–466. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Goto H, Tsubota K, Nemoto R, Ueda S, Umazume K, Usui Y and Matsumura H: Clinical features and prognosis of sebaceous carcinoma arising in the eyelid or conjunctiva. Jpn J Ophthalmol. 64:549–554. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Owen JL, Kibbi N, Worley B, Kelm RC, Wang JV, Barker CA, Behshad R, Bichakjian CK, Bolotin D, Bordeaux JS, et al: Sebaceous carcinoma: Evidence-based clinical practice guidelines. Lancet Oncol. 20:e699–e714. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Tang S, Li S, Liu T, He Y, Hu H, Zhu Y, Tang S and Zhou H: MicroRNAs: Emerging oncogenic and tumor-suppressive regulators, biomarkers and therapeutic targets in lung cancer. Cancer Lett. 502:71–83. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Bladen JC, Wang J, Sangaralingam A, Moosajee M, Fitchett C, Chelala C, Beaconsfield M, O'Toole EA, Philpott MP and Ezra DG: MicroRNA and transcriptome analysis in periocular Sebaceous Gland Carcinoma. Sci Rep. 8:75312018. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Tetzlaff MT, Curry JL, Yin V, Pattanaprichakul P, Manonukul J, Uiprasertkul M, Manyam GC, Wani KM, Aldape K, Zhang L, et al: Distinct pathways in the pathogenesis of sebaceous carcinomas implicated by differentially expressed microRNAs. JAMA Ophthalmol. 133:1109–1116. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Tetzlaff MT, Singh RR, Seviour EG, Curry JL, Hudgens CW, Bell D, Wimmer DA, Ning J, Czerniak BA, Zhang L, et al: Next-generation sequencing identifies high frequency of mutations in potentially clinically actionable genes in sebaceous carcinoma. J Pathol. 240:84–95. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Bao Y, Selfridge JE, Wang J, Zhao Y, Cui J, Guda K, Wang Z and Zhu Y: Mutations in TP53, ZNF750, and RB1 typify ocular sebaceous carcinoma. J Genet Genomics. 46:315–318. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Tetzlaff MT, Curry JL, Ning J, Sagiv O, Kandl TL, Peng B, Bell D, Routbort M, Hudgens CW, Ivan D, et al: distinct biological types of ocular adnexal sebaceous carcinoma: HPV-driven and virus-negative tumors arise through nonoverlapping molecular-genetic alterations. Clin Cancer Res. 25:1280–1290. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zaslavsky A, Baek KH, Lynch RC, Short S, Grillo J, Folkman J, Italiano JE Jr and Ryeom S: Platelet-derived thrombospondin-1 is a critical negative regulator and potential biomarker of angiogenesis. Blood. 115:4605–4613. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Yang W, Li W, Pan F, Yang XY, Zhao X, Qin L and Pan Y: TSP-1 as a novel biological marker of tumor vasculature normalization in colon carcinoma induced by Endostar. Oncol Lett. 19:2107–2114. 2020.PubMed/NCBI
|
|
34
|
Sevilla-Montero J, Bienes-Martínez R, Labrousse-Arias D, Fuertes-Yebra E, Ordóñez Á and Calzada MJ: pVHL-mediated regulation of the anti-angiogenic protein thrombospondin-1 decreases migration of clear cell renal carcinoma cell lines. Sci Rep. 10:11752020. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Rouanne M, Adam J, Goubar A, Robin A, Ohana C, Louvet E, Cormier J, Mercier O, Dorfmüller P, Fattal S, et al: Osteopontin and thrombospondin-1 play opposite roles in promoting tumor aggressiveness of primary resected non-small cell lung cancer. BMC Cancer. 16:4832016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Pal SK, Nguyen CT, Morita KI, Miki Y, Kayamori K, Yamaguchi A and Sakamoto K: THBS1 is induced by TGFB1 in the cancer stroma and promotes invasion of oral squamous cell carcinoma. J Oral Pathol Med. 45:730–739. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Cen J, Feng L, Ke H, Bao L, Li LZ, Tanaka Y, Weng J and Su L: Exosomal thrombospondin-1 disrupts the integrity of endothelial intercellular junctions to facilitate breast cancer cell metastasis. Cancers (Basel). 11:112019. View Article : Google Scholar
|
